Overview

S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer

Status:
Completed

Trial end date:
2017-06-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether hormone therapy plus mitoxantrone and prednisone is more effective than hormone therapy alone for prostate cancer. PURPOSE: This randomized phase III trial is studying hormone therapy, mitoxantrone, and prednisone to see how well they work compared to hormone therapy alone in treating patients who have undergone radical prostatectomy for prostate cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Southwest Oncology Group

Collaborators:

Cancer and Leukemia Group B
National Cancer Institute (NCI)

Treatments:

Androgens
Bicalutamide
Goserelin
Mitoxantrone
Prednisone